#Sleep apnea

2 stories

Research April 10, 2026 · View digest

GLP-1 Receptor Agonists Expanding Clinical Scope Beyond Glycemic Control

A new review highlights GLP-1 RAs achieving a 55% reduction in apnea-hypopnea index and 14.9% mean weight loss in non-diabetic populations, with pleiotropic effects across cardiovascular, renal, and skeletal systems.

Clinical Trials April 2, 2026 · View digest

APhA2026 Highlights GLP-1 Expansion into Kidney Disease and Sleep Apnea

At APhA2026, semaglutide's FLOW trial showed 24% reduction in major kidney events in CKD patients, while tirzepatide's SURMOUNT-OSA trial demonstrated dramatic reductions in sleep apnea severity.